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Epstein-Barr virus (EBV) infection is associated with the development of many B-cell lymphomas, including
Burkitt’s lymphoma, Hodgkin’s lymphoma, and posttransplant lymphoproliferative disease. The virus alters a
diverse range of cellular molecules, which leads to B-cell growth and immortalization. This study was initiated
to investigate the interplay between EBV and a proapoptotic transcription factor target, FoxO1. In this report,
we show that EBV infection of B cells leads to the downregulation of FoxO1 expression by phosphatidylinositol
3-kinase-mediated nuclear export, by inhibition of FoxO1 mRNA expression, and by alteration of posttrans-
lational modifications. This repression directly correlates with the expression of the FoxO1 target gene Bcl-6
and inversely correlates with the FoxO1-regulated gene Cyclin D2. Expression of the EBV genes for latent
membrane protein 1 and latent membrane protein 2A decreases FoxO1 expression. Thus, our data elucidate
distinct mechanisms for the regulation of the proapoptotic transcription factor FoxO1 by EBV.
Epstein-Barr virus (EBV) is a member of the human -her-
pesvirus family. Greater than 90% of the adult population
worldwide is infected with the virus. In the majority of cases,
EBV infection is asymptomatic for the lifetime of the host due
to cytotoxic T-lymphocyte-mediated targeting of infected cells
(42). EBV primarily infects B cells but has also been reported
to infect T cells and epithelial cells. Primary infection with
EBV during adolescence or adulthood can be accompanied by
the development of a self-limiting T-cell lymphocytosis known
as infectious mononucleosis. However, EBV is also potentially
oncogenic. The virus has been detected in malignancies of
lymphoid as well as epithelial origin (41). The EBV genome is
detected in most cases of posttransplant lymphoproliferative
disease, where patients are immunosuppressed and thus can-
not control the proliferation of virus-infected cells (36). Essen-
tially every case of endemic Burkitt’s lymphoma (BL) is EBV
positive, in contrast with between 10 and 90% of sporadic
cases. The virus has also been implicated in cases of Hodgkin’s
lymphoma, nasopharyngeal carcinoma, and some T-cell lym-
phomas.
The in vitro infection of primary B cells with EBV leads to
the establishment of immortalized lymphoblastoid cell lines
(LCLs). The cooperative actions of several EBV genes con-
tribute to this effect by generating survival and proliferation
signals (56). Activation of the transcription factor NF-B and
the phosphatidylinositol 3-kinase (PI3K)/protein kinase B
(PKB) signaling pathway has been shown to play an important
role in the regulation of survival and proliferation of B cells
(6). While many of the targets of NF-B have been character-
ized, the nuclear targets of PI3K are relatively poorly charac-
terized for EBV-immortalized B cells.
Proapoptotic forkhead box class O (FoxO) transcription fac-
tors are direct targets of PI3K-mediated signal transduction in
a variety of cell systems. Phosphorylation of members of this
transcription factor family by PKB, the main downstream ef-
fector of PI3K activity, results in the nuclear exclusion and
inhibition of transcriptional activity (3, 9, 49). FoxO transcrip-
tion factors coordinate cell cycle progression and cell survival
by the activation of antiproliferative genes, such as those en-
coding p27Kip1 and cyclin G2, as well as proapoptotic genes,
such as those encoding Fas ligand (FasL), Bcl-6, and the Bcl-2
family member Bim (9, 13, 15, 20, 33, 50). Initial identification
of this transcription factor family in humans occurred when
three members were identified at chromosomal translocations
in human tumors, namely, FoxO1 (FKHR) in alveolar rhabdo-
myosarcomas, FoxO3a (FKHR-L1) in acute myeloblastic leu-
kemia, and FoxO4 (AFX) in acute lymphocytic leukemia (5,
11, 21, 22, 38). These discoveries were the first indications that
FoxO transcription factors have a role in tumor development.
Recent studies have demonstrated that a loss of FoxO activi-
ties due to protein degradation contributes to cellular trans-
formation of primary breast cancer tumors (23) and mouse
primary lymphomas (24).
This study was initiated to investigate the interplay between
FoxO1 and EBV. We focused on one member of the FoxO
family, FoxO1, and have shown that it is downregulated in
EBV-infected B cells. This repression was found to correlate
with the expression of two FoxO1 target genes, bcl-6 and cyclin
D2. PI3K regulation of FoxO1 protein levels and subcellular
localization were also found to differ between EBV-negative
and -positive B-cell lines. In addition, two EBV proteins, latent
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membrane protein 1 (LMP1) and LMP2A, have been identi-
fied as sufficient for the downregulation of FoxO1 expression.
MATERIALS AND METHODS
Cell culture. All cell lines were cultured in RPMI 1640 medium supplemented
with 10% fetal calf serum, 2 mM L-glutamine, and antibiotics (200 U/ml peni-
cillin and 200 g/ml streptomycin) and were maintained at 37°C in a 5% CO2
humidified incubator.
Nuclear and cytosolic protein extraction. Nuclear and cytosolic extracts were
generated using a modification of a previously published protocol (8). Following
the application of inhibitors as indicated, 1  107 cells were harvested and placed
on ice. They were washed in 1 ml of hypotonic buffer (10 mM HEPES [pH 7.9],
1.5 mM magnesium chloride, 10 mM potassium chloride, 10 mM phenylmethyl-
sulfonyl fluoride [PMSF]) and centrifuged at 10,000  g for 1 min. Cells were
lysed in 100 l of hypotonic buffer with 0.1% Nonidet P-40 and placed on ice for
5 min. The mixture was centrifuged for 5 min at 10,000  g. The supernatant was
removed and retained as the cytosolic fraction. The remaining pellet was incu-
bated with 60 l of high-salt buffer (20 mM HEPES [pH 7.9]), 420 mM NaCl, 1.5
mM MgCl2, 25% glycerol, 0.5 mM PMSF) to release the transcription factors
from the DNA. This mixture was incubated on ice for 15 min and centrifuged for
5 min at 10,000  g. The supernatant was retained as the nuclear fraction and
stored at 20°C until further use.
Transfection, Western blotting, and antibody detection. For transient trans-
fections, 1  107 DG75 cells from a suspension culture were transfected by
electroporation using a Bio-Rad Genepulser II electroporator at 300 V and 950
F at room temperature in 500 l growth medium. Following electroporation,
the cells were transferred to 3.5 ml of fresh medium per sample and incubated
at 37°C in a 5% CO2 humidified incubator for 20 h. Total protein lysates were
generated using the passive lysis buffer provided with the Promega Dual Lucif-
erase reporter assay system (E-1910). The lysates were clarified by centrifugation
at 13,000  g for 5 min, and the soluble fraction was added to an equal volume
of 2 gel sample buffer (0.1 M Tris buffer, pH 6.8, 0.2 M dithiothreitol, 4%
sodium dodecyl sulfate [SDS], 20% glycerol, 0.1% bromophenol blue) and boiled
for 5 min. Proteins were separated by SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to polyvinylidene difluoride (PVDF) membranes
(Amersham) for immunoblotting. Specific antibody-protein complexes were de-
tected using alkaline phosphatase-conjugated secondary antibodies and CDP-
Star (Tropix) chemiluminescence reagent.
Antibodies to poly(ADP) ribose polymerase (PARP; sc-7150), cyclin D2 (sc-
593), Bcl-6 (sc-858), and calregulin (sc-11398) were obtained from Santa Cruz
Biotechnology and used at a concentration of 200 ng/ml. An antibody to FoxO1
(9462) was purchased from Cell Signaling Technologies and used at a 1/1,000
dilution of the stock supplied. An antibody to actin (A-2066), obtained from
Sigma, was used at a 1/1,000 dilution of the stock supplied. Anti-LMP1 (CS.1-4)
(45), anti-EBNA2A (PE2) (55), and anti-LMP2A (14B7) (18) monoclonal anti-
bodies have been described previously.
DNA affinity precipitation. Nuclear extracts were diluted with 20 volumes of
salt-free buffer (50 mM Tris-HCl, pH 8, 0.25 mM EDTA, 10 mM NaF, 25%
glycerol, 0.5 mM PMSF, 10 l/ml phosphatase inhibitor cocktail I [P-2850;
Sigma] and phosphatase inhibitor cocktail II [P-5726], 1 mM NaVO4). Strepta-
vidin-conjugated agarose beads (30 l of a 50% slurry) and a biotinylated dou-
ble-stranded oligonucleotide (1 g) were added to the lysate, which was rotated
for 1 h at 4°C. The mixture was centrifuged at 12,000  g, and the supernatant
was removed. The beads were washed in buffer three times, and the proteins
were eluted from the beads by the addition of 2 gel sample buffer (0.1 M Tris
buffer, pH 6.8, 0.2 M dithiothreitol, 4% sodium dodecyl sulfate, 20% glycerol,
0.1% bromophenol blue) for one-dimensional analysis by SDS-PAGE. Proteins
were eluted from the beads by the addition of sample buffer {7 M urea, 2 M
thiourea, 0.4% 3-[(3-cholamidopropyl)-dimethylamino]-1-propanesulfonate (CHAPS)}
for analysis by two-dimensional (2D) electrophoresis. Separated proteins were
transferred to PVDF membranes and analyzed using specific antibodies. The
sequence of the oligonucleotide corresponding to the bim promoter was CAG
AGTTACTCCGGTAAACACGCCAGGGAC (15).
2D electrophoresis. DNA affinity-precipitated proteins were eluted from
streptavidin-coated agarose beads using 100 l sample buffer (7 M urea, 2 M
thiourea, 0.4% CHAPS). A 7-cm pH 3-10 NL Immobiline Drystrip gel (IPG;
Amersham) was rehydrated for 12 h at 20°C with 80 l of the eluted sample in
a total volume of 125 l of sample buffer supplemented with 50 mM dithiothre-
itol, 1% bromophenol blue, and 0.5% IPG pH 3-10 NL buffer (Amersham).
Isoelectric focusing (IEF) of the samples was performed on an Ettan IPGphor II
IEF system using the following program: 1 h at 500 V; 2 h at 1,000 V (gradient);
1 h at 1,000 V and 2 h at 8,000 V (gradient); and 8 h at 8,000 V. IPG strips were
then equilibrated for 15 min in equilibration buffer (1 NuPAGE LDS sample
buffer; Invitrogen) containing 10 NuPAGE sample reducing agent (0.5 ml)
(Invitrogen). The IPG strips were subsequently equilibrated for 15 min in equil-
ibration buffer containing 125 mM iodoacetamide. Equilibrated IPG strips were
transferred to the IPG wells of NuPAGE 4 to 12% bis-Tris Zoom gels (Invitro-
gen) and separated in the second dimension for 1 h at 200 V. Separated proteins
were subsequently transferred to PVDF membranes and analyzed by Western
blotting as described previously.
Real-time quantitative reverse transcription-PCR. Total cellular RNA was
isolated using an RNeasy kit (QIAGEN) according to the manufacturer’s in-
structions. RNAs were treated with RNase-free DNase I (QIAGEN) for subse-
quent real-time quantitative PCR. Total RNA was reverse transcribed with
Superscript III reverse transcriptase (Invitrogen). The resulting cDNAs were
amplified using an ABI Prism 7700 sequence detection system (Applied Biosys-
tems, Foster City, CA) with the following primer pairs: FOXO1-sense (TGG
ACA TGC TCA GCA GAC ATC), FOXO1-antisense (TTG GGT CAG GCG
GTT CA), L19-sense (GCG GAA GGG TAC AGC CAA T), and L19-antisense
(GCA GCC GGC GCA AA). L19, a nonregulated ribosomal housekeeping
gene, was used as an internal control to normalize input RNA. All measurements
were performed in triplicate (28).
Plasmids. The pSG5 empty vector, pSG5-LMP1 (25), pSG5-LMP1AAA (14),
and pSG5-LMP2A (29) have been described previously. The Bcl-6Bcl-6-lucif-
erase reporter was a kind gift from Tracy Tang and Laurence Lasky (Genentech
Inc., South San Francisco, Calif.) and has been described previously (16, 50). The
phRL-SV40 luciferase reporter vector was purchased from Promega (E-6261).
Inducible expression of LMP1, LMP2A, and EBNA2A in stable transfectants.
Stable DG75 transfectants containing an inducible LMP1, LMP2A, or EBV
nuclear antigen 2A (EBNA2A) gene (17) were maintained under drug selection
and in 1 g/ml tetracycline until required. Prior to each experiment, cells were
washed five times in RPMI 1640 medium and were recultured without drug
selection and in the presence or absence of 1 g/ml tetracycline for a period of
either 24 or 48 h. For the generation of total cell lysates, cells were counted on
a hemocytometer and resuspended in 50 l phosphate-buffered saline per 106
cells. An equal volume of 2 gel sample buffer (125 mM Tris-HCl, pH 6.8, 20%
glycerol, 0.4 M sodium 2-mercaptoethane sulfonate, 4% SDS, 0.02% bromophe-
nol blue) was added, and the cells were sonicated using a W385 sonicator (Heat
Systems Ultrasonics). Following sonication, samples were heated at 100°C for 5
min. The solubilized proteins were separated by SDS-PAGE and transferred to
a PVDF membrane (Amersham) for immunoblotting as described above.
RESULTS
FoxO1 expression is downregulated by EBV infection. To
investigate the relationship between EBV infection and FoxO1
expression, nuclear FoxO1 protein levels were analyzed by
Western blotting, using cell lines with different EBV status and
a specific antibody. PARP protein levels were also analyzed to
verify equal protein loading, as PARP is found in the nucleus
and PARP expression levels are not affected by EBV status.
BL41, BL41B95.8, and IARC-171 are from the same indi-
vidual and thus have the same genetic background. They differ
in their patterns of EBV gene expression and the presence of
the myc translocation in BL41 that is typical of Burkitt’s lym-
phoma cells (44). BL41 is an EBV-negative BL line.
BL41B95.8 is the same line after infection with the B95.8
strain of EBV. IARC-171 is an EBV B95.8-immortalized LCL
derived from the same patient as BL41 (Fig. 1a). Our results
show high levels of FoxO1 protein expression in the EBV-
negative BL line (BL41). In contrast, FoxO1 expression was
markedly downregulated in EBV-immortalized B cells (IARC-
171). To investigate whether the presence of EBV was the
cause of downregulation, FoxO1 expression was also analyzed
in BL41B95.8 cells. Less FoxO1 was detected in BL41B95.9
cells than in BL41 cells, suggesting that EBV gene products have
a role in downregulating FoxO1 protein expression.
EBV infection of B cells can lead to the establishment of
distinct latency programs as a result of the different expression
11192 SHORE ET AL. J. VIROL.
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patterns of viral genes (27). To establish whether the latency
program affects FoxO1 expression, protein levels were com-
pared using four EBV-positive sublines of a BL tumor. Mutu I
cells express only EBNA1 and two small polyadenylated RNA
molecules (EBER1 and EBER2), a restricted pattern of viral
gene expression termed latency I. Mutu III cells express the
full complement of EBV latency genes (EBNA1, EBNA2,
EBNA3A, EBNA3B, EBNA3C, EBNA-LP, LMP1, LMP2,
EBER1, EBER2, and BamHI A rightward transcripts), termed
the latency III pattern (43). Our results clearly demonstrate
that a latency III pattern of viral gene expression is required
for the repression of FoxO1 protein levels (Fig. 1b).
Additional EBV-negative and -positive lines were also tested
for FoxO1 protein expression (Fig. 1c). Three EBV-negative
Burkitt’s lymphoma lines were analyzed. BL41 is described
above. DG75 is another EBV-negative BL line (2). AK31 is an
EBV-negative subclone of Akata (26), an EBV-positive BL
line displaying a latency I pattern of gene expression. Again,
FoxO1 protein expression was high in EBV-negative tumor
lines. Three LCLs were also tested. IARC-171 is described
above. IB4-LCL is an LCL generated from cord blood B cells
immortalized with EBV B95.8 (46). EB-LCL is an LCL gen-
erated in-house by infection of primary B cells from the blood
of a healthy donor with the B95.8 strain of EBV. In accordance
with previous results, FoxO1 expression was very low in EBV-
immortalized B cells. The level of FoxO1 expression in the
BL41B95.8 cells was again between those observed in BL41
and IARC-171 cells.
PI3K inhibition increases nuclear FoxO1. One mechanism
whereby FoxO activity is regulated is by nuclear exclusion and
subsequent degradation once it is in the cytoplasm. Stimulation
of the PI3K pathway has a central role in this process by
activating the kinase activity of PKB. FoxO transcription fac-
tors contain three consensus PKB phosphorylation sites that,
when phosphorylated, target the proteins for nuclear exclu-
sion, thereby increasing the survival potential of the cell (4). In
order to investigate the role of PI3K in regulating the subcel-
lular localization and protein levels of FoxO1, a specific inhib-
itor of PI3K, LY294002, was employed (52). BL41 and IARC-
171 cells were either left untreated or treated with increasing
doses of LY294002. Nuclear and cytosolic FoxO1 protein lev-
els were subsequently analyzed by Western blotting.
Although basal levels of FoxO1 were relatively high in the
nuclei of BL41 cells, this could be increased further following
PI3K inhibition by LY294002 for 1 h (Fig. 2a). In parallel with
this increase, a decrease in cytosolic FoxO1 was observed fol-
lowing LY294002 treatment. In contrast, no nuclear increase
or cytosolic decrease in FoxO1 level could be detected in the
LCL (IARC-171) after 1 h of treatment with the PI3K inhib-
itor (data not shown). Only after treatment with LY294002 for
24 h could an increase in FoxO1 nuclear protein be detected
(Fig. 2b). This increase was not accompanied by a decrease in
cytosolic FoxO1. These results show that PI3K inhibition can
increase the FoxO1 level in both cell types, but with distinct
mechanisms, suggesting a difference in the ways in which PI3K
regulates FoxO1 activity in cells with different EBV statuses.
The slow kinetics of upregulation of FoxO1 by treatment
with LY294002 in IARC-171 cells suggests a different mecha-
nism of regulation in these cells. For this reason, we investi-
gated whether FoxO1 repression by EBV could occur at the
transcriptional level. Total RNAs were purified from BL41,
BL41B95.8, and IARC-171 cells, and FoxO1 mRNA activity
was measured relative to that of a housekeeping gene (L19) by
real-time PCR. The results showed that steady-state levels of
FoxO1 mRNA were reduced by half in EBV-infected cells
compared to those in EBV-negative cells (Fig. 2c), indicat-
ing that FoxO1 is downregulated at the transcriptional level
by EBV.
FoxO1 can bind DNA and is posttranslationally modified in
EBV-infected cells. DNA binding is required for transcription
factors to regulate target genes and downstream effects. It was
therefore important to check whether the FoxO1 protein de-
tected was capable of binding DNA for mediation of its effects
on cell proliferation and survival. DNA affinity precipitation
experiments were therefore carried out using an oligonucleo-
tide containing a forkhead response element (5-TAAACAC-
3) from the bim promoter (15). FoxO1 molecules from nu-
clear extracts of BL41 and BL41B95.8 cells, either left
untreated or treated with LY294002 (20 M) for 1 h, were
DNA affinity precipitated using the bim promoter oligonucle-
otide. FoxO1 DNA binding was subsequently analyzed by
Western blotting (Fig. 3a). DNA binding of FoxO1 to the bim
promoter oligonucleotide was detected in untreated BL41 and
BL41B95.8 cells, confirming that the FoxO1 protein detected
is capable of binding to target promoter sequences. The effect
of PI3K inhibition on DNA binding was also tested. Following
LY294002 treatment, the amount of DNA-bound FoxO1 was
significantly increased, to similar degrees, in both BL41 and
FIG. 1. EBV infection downregulates FoxO1 expression. Nuclear
protein extracts were generated from the following cell lines: (a) a
Burkitt’s lymphoma cell line (BL41), an EBV-infected Burkitt’s lym-
phoma line (BL41B95.8), and a lymphoblastoid B-cell line (IARC-
171); (b) an EBV-positive Burkitt’s line expressing latency I genes
(Mutu I, clones 59 and 179) and an EBV-positive Burkitt’s line ex-
pressing latency III genes (Mutu III, clones 62 and 95); and (c) EBV-
negative BL lines (BL41, DG75, and AK31), an EBV-positive BL line
(BL41B95.8), and lymphoblastoid cell lines (IB4-LCL, IARC-171,
and EB-LCL). Proteins were resolved by SDS-PAGE, and FoxO1
protein levels were determined by immunoblotting with a specific
FoxO1 antibody. PARP was used as a loading control.
VOL. 80, 2006 EBV REPRESSES FoxO1 THROUGH LMP1 AND LMP2A 11193
 o
n
 February 25, 2014 by Cardiff Univ
http://jvi.asm.org/
D
ow
nloaded from
 
BL41B95.8 cells. This suggests that a direct correlation exists
between the amount of FoxO1 localized within the nucleus and
DNA binding.
The role of posttranslational modifications in the regulation
of transcription factor activity is well established. Phosphory-
lation events are well known to have important effects on the
activities of many transcription factors. FoxO members contain
multiple PKB phosphorylation sites that mediate subcellular
localization and DNA binding activity. Both ubiqitinylation
and acetylation have also been reported to modulate members
of the FoxO family by directing degradation and attenuation of
DNA binding, respectively (24, 32, 39). To establish how many
isoforms of FoxO1 exist in the nuclei of EBV-negative and
-positive BL41 cells, FoxO1 was analyzed by 2D electrophore-
sis (Fig. 3b). DNA affinity-precipitated FoxO1 eluted from bim
promoter oligonucleotides was isoelectrically focused, using a
pH 3-to-10 nonlinear immobilized pH gradient, and subse-
quently separated in the second dimension by SDS-PAGE.
Western blot detection of FoxO1 with a specific antibody re-
vealed that multiple isoforms of FoxO1 bind to DNA in
BL41B95.8 cells. The isoelectric points (pI) of the different
FoxO1 isoforms range between 5.4 and 6.1, and the isoforms
are present in various amounts. The most abundant isoform
has a pI of approximately 5.7. In contrast, only one isoform of
FoxO1 could be detected in BL41 cells, with a lower pI value
of approximately 4.7. We can therefore conclude that FoxO1 is
posttranslationally modified and that multiple isoforms of
FoxO1 are capable of binding DNA in EBV-positive cells
(BL41B95.8) but not in an EBV-negative B-cell line (BL41).
FoxO1 expression correlates with Bcl-6 expression and in-
versely correlates with cyclin D2 expression. Having estab-
lished that the FoxO1 protein detected was capable of binding
DNA, it was then important to determine whether DNA bind-
ing initiated transcriptional activation and to measure the ef-
fect of EBV on target gene activity. To address these issues,
expression levels of FoxO1 target genes were analyzed by using
various cell lines (Fig. 4). Bcl-6 is a sequence-specific transcrip-
tional repressor of proteins mediating lymphocyte apoptosis
and differentiation, and bcl-6 transcription is activated by
FoxO1 (50). Nuclear Bcl-6 from various cell lines was analyzed
by Western blotting. A direct correlation between FoxO1 and
Bcl-6 protein levels was observed, with a high level of Bcl-6
expression in cells with high FoxO1 expression and less Bcl-6
detected in EBV-transformed LCL cells. The Bcl-6 levels did
FIG. 2. PI3K inhibition can increase nuclear FoxO1 in all cell types, but with different kinetics. Nuclear and cytosolic protein extracts were
generated from (a) BL41 and (b) IARC-171 B-cell lines. Proteins were resolved by SDS-PAGE and immunoblotted with the anti-FoxO1 antibody.
Cells were either left untreated or treated with various concentrations of LY294002 (20 M, 10 M, and 5 M) for either 1 h (BL41) or 24 h
(IARC-171). Human anti-actin was used as a loading control. (c) The expression of FoxO1 RNA was analyzed by real-time PCR and normalized
to the level of L19. The results shown are the averages of triplicate results.
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not correspond with EBV status per se, as Akata cells, which
are EBV positive but have a latency I pattern of gene expres-
sion, expressed high levels of FoxO1 and Bcl-6. This agrees
with the data for Mutu I cells and suggests that one or more of
the EBV genes expressed in latency III are likely to regulate
FoxO1. Cyclin D2 protein levels were also analyzed. Cyclin D2
is a cell cycle protein required for progression through the G1
phase of the cell cycle and has been shown to be repressed
transcriptionally by FoxO (16, 47). Western blot analysis
showed an inverse correlation between cyclin D2 expression
and the expression of both FoxO1 and Bcl-6. These data sug-
gest that FoxO1 is transcriptionally active and that the repres-
sive effect that EBV has upon FoxO1 also extends to its target
genes.
Both LMP1 and LMP2A can downregulate FoxO1 expres-
sion. The establishment of EBV latency requires the expres-
sion of a repertoire of EBV-carried latent genes. LMP1 is the
major transforming protein of EBV and is required for the
transforming effects of EBV on primary B cells. LMP1 mimics
constitutively activated CD40, a member of the tumor necrosis
factor receptor superfamily, mediating ligand-independent sig-
naling through a range of key signaling pathways essential for
survival, including the NF-B, mitogen-activated protein ki-
nase, Jun N-terminal protein kinase (JNK), p38, and JAK/
STAT pathways as well as the PI3K pathway (56). LMP2A,
which is also encoded by EBV, is another potent activator of
the PI3K pathway, acting as a constitutively activated B-cell
receptor (BCR), thereby inhibiting normal signaling through
the BCR (34, 48). Since the activities of both LMP1 and
LMP2A have been shown to activate PI3K signaling, it was
reasonable to suspect that they may have a role in the repres-
sion of FoxO1.
To test this hypothesis, DG75 cells, which express high levels
of FoxO1, were transiently transfected with increasing
amounts of either an LMP1 or LMP2A expression vector.
After 20 h, cells were harvested and lysed, and FoxO1 and
Bcl-6 protein levels were analyzed by Western blotting. DG75
cells transfected with LMP1 demonstrated reduced levels of
FoxO1 and Bcl-6 protein expression in a dose-dependent man-
ner (Fig. 5a). A reporter plasmid carrying a Bcl-6 promoter
containing a FoxO consensus binding sequence (50) was also
repressed by LMP1 in a dose-dependent manner (data not
shown). Protein analysis of LMP2A-transfected cells showed a
similar decrease of FoxO1 expression. A clear downregulation
of Bcl-6 was also detected with transfection of 10 g of
LMP2A. However, at the lower doses of 1 and 5 g, LMP2A
did not repress Bcl-6 protein expression (Fig. 5b). Transfection
of DG75 cells with an EBNA2A expression vector did not
repress either the protein level of FoxO1 or Bcl-6 or the tran-
scriptional activity of the Bcl-6 gene (not shown).
To further analyze the effects of LMP1, LMP2A, and
EBNA2A on protein levels of FoxO1 and Bcl-6, protein ex-
pression levels were analyzed in stable DG75 transfectants
containing an inducible LMP1, LMP2A, or EBNA2A gene.
Protein levels were compared with those detected in two lym-
phoblastoid cell lines, namely, IARC-171 and an early-passage
LCL (CMc) generated from the B cells of a healthy donor with
the B95.8 strain of EBV (Fig. 6). In the presence of tetracy-
FIG. 3. FoxO1 can bind DNA and is present in multiple forms.
Nuclear protein extracts were generated from BL41 and BL41B95.8
cells. Nuclear proteins were subsequently DNA affinity precipitated
using streptavidin-coated agarose beads with or without biotinylated
bim oligonucleotides. Bound proteins were eluted, resolved by SDS-
PAGE, and immunoblotted using the anti-FoxO1 antibody. (a) BL41
and BL41B95.8 cells left untreated or treated with LY294002 (20
M, 1 h). (b) DNA affinity-precipitated (using the bim oligonucleo-
tide) proteins from BL41 and BL41B95.8 cells treated with
LY294002 (20 M, 1 h) were analyzed by 2D electrophoresis. Eluted
proteins were isoelectrically focused using a pH 3-to-10 nonlinear
immobilized pH gradient and separated in the second dimension by
SDS-PAGE. FoxO1 isoforms were detected by immunoblotting with
the anti-FoxO1 antibody.
FIG. 4. Expression of FoxO1 correlates with expression of Bcl-6
and inversely correlates with expression of cyclin D2. Nuclear protein
extracts were generated from the following B-cell lines with various
EBV statuses: BL41, an EBV-negative BL line; BL41B95.8, an EBV-
positive BL line (latency III); three EBV-positive LCLs (IARC-171,
EB-LCL, and IB4-LCL); and Akata, an EBV-positive BL line express-
ing the latency I pattern. Proteins were resolved by SDS-PAGE and
subsequently analyzed by immunoblotting with specific antibodies to
FoxO1, Bcl-6, and cyclin D2. PARP was used as a loading control.
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cline, protein expression of FoxO1 and Bcl-6 was clearly de-
tectable in EBNA2A-, LMP1-, and LMP2A-inducible lines,
although FoxO1 expression was higher in the EBNA2A line
and the parent DG75 cells (not shown). Upon induction of
LMP1 gene expression by reculturing the cells in the absence
of tetracycline, clear decreases in both FoxO1 and Bcl-6 levels
were detected at 24 h and, to a greater degree, at 48 h. The
induction of LMP2A expression did not significantly reduce
FoxO1 expression. However, the FoxO1 level was lower in the
DG75 cells that contained LMP2A, even when they were cul-
tured in the presence of tetracycline, than in cells with the
tetracycline transactivator alone (not shown) or cells express-
ing EBNA2A. The cells clearly also expressed LMP2A. How-
ever, the induction of higher levels of LMP2A caused a de-
crease in Bcl-6 protein levels, suggesting that LMP2A may
contribute to the regulation of this protein in a FoxO1-inde-
pendent fashion. Similar to the LMP2A level, the FoxO1 level
in the LMP1-inducible line was reduced compared to that in
the EBNA2A line. Together, these observations demonstrate
the sensitivity of FoxO1 protein expression to the residual low
levels of both LMP1 and LMP2A signals in the presence of
tetracycline. Induction of EBNA2A did not affect the expres-
sion of FoxO1 or Bcl-6. The results from the transiently trans-
fected and stable lines demonstrate that both LMP1 and
LMP2A can downregulate the expression of FoxO1.
LMP1 gave a more dramatic downregulation of FoxO1 than
did LMP2A. There has been significant analysis of LMP1 sig-
FIG. 5. Roles for LMP1 and LMP2A in FoxO1 downregulation.
DG75 cells were transfected with various amounts of (a) LMP1 and (b)
LMP2A expression vectors. Cells were harvested, and lysates gener-
ated were analyzed by SDS-PAGE and Western blotting. Protein levels
of FoxO1 and Bcl-6 were analyzed using specific antibodies. LMP1 and
LMP2A protein levels were also checked using specific antibodies.
Actin was used as a loading control.
FIG. 6. Inducible LMP1 and LMP2A downregulate FoxO1 and
Bcl-6. (a) Stable DG75 transfectants containing an inducible
EBNA2A, LMP1, or LMP2A gene were maintained under drug selec-
tion and with 1 g/ml tetracycline until required for experiments.
When required, cells were washed five times with RPMI 1640 medium
and were recultured without drug selection and in the presence or
absence of 1 g/ml tetracycline for a period of either 24 (1) or 48 h
(2). Protein levels of FoxO1 and Bcl-6 were subsequently analyzed
using specific antibodies. Protein expression levels were also analyzed
in the IARC-171 and CMc lymphoblastoid cell lines. EBNA2A, LMP1,
and LMP2A protein levels were also checked using specific antibodies.
Calregulin was used as a loading control. (b) In a similar experiment to
that described in the legend to Fig. 5, three different amounts of an
expression vector for wild-type and a mutant LMP1 (LMP1AAA) were
transiently transfected into DG75 cells. Cells were harvested, and the
lysates generated were analyzed by SDS-PAGE and Western blotting.
Protein levels of FoxO1, Bcl-6, LMP1, and STAT1 were analyzed using
specific antibodies. Actin was used as a loading control.
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naling that has identified at least two different signaling do-
mains, CTAR1 and CTAR2. CTAR1 has been shown to acti-
vate PI3K in epithelial cells and fibroblasts (12, 30). To
determine whether CTAR1 can regulate FoxO1, we expressed
a mutant that had three amino acids changed in this domain,
entitled LMP1AAA, where proline 204, glycine 206, and threo-
nine 208 were all mutated to alanine. Three different amounts
of an expression vector for wild-type LMP1 or LMP1AAA were
transiently transfected into DG75 cells, and the cells were left
for 24 hours. After this time, the cells were harvested and lysed
by the addition of gel loading buffer. The protein extract was
resolved by SDS-PAGE and transferred to a PVDF mem-
brane, and the levels of four different proteins were detected
by specific antibodies (Fig. 6b). Both wild-type LMP1 and the
LMP1AAA mutant were able to cause a decrease in FoxO1 and
Bcl-6 protein levels. However, only wild-type LMP1 was able to
induce STAT1, a transcription factor that is increased by
LMP1 through an NF-B pathway (40). These data show that
distinct domains of LMP1 are involved in the distinct regula-
tion of transcription factor protein levels and that this may not
be due to the direct activation of PI3K by this molecule.
DISCUSSION
This study was performed to investigate the interplay be-
tween EBV and FoxO1. Our data clearly demonstrate that
EBV has a repressive effect on FoxO1 protein expression in B
cells and that this effect can be mediated by both latent mem-
brane proteins 1 and 2A. The repression of FoxO1 may be due
to the ability of these membrane proteins to activate PI3K
signaling, although our data show that EBV can also repress
FoxO1 mRNA levels, suggesting alternative mechanisms for
the regulation of this molecule.
FoxO1 has a well-established role in the regulation of cell
survival, and thus it is logical to suspect that it is a target of
regulation by EBV. It is important, however, that all of the cell
lines used in this study proliferate, suggesting that FoxO1 reg-
ulation can be circumvented, perhaps by the c-myc oncogene,
in Burkitt’s lymphoma cells. In this study, a correlation was
observed between EBV status and the activities of the FoxO
target genes Bcl-6 and cyclin D2, which are essential for B-cell
proliferation and development. The level of Bcl-6, a direct
target gene for activation by FoxO (50), correlated with FoxO1
expression. However, this does not prove that Bcl-6 is a direct
target in these cells. The introduction of a FoxO1 transgene
into an LCL, probably in some system that allows regulated
gene expression, could be used to directly identify FoxO1 tar-
get genes in EBV-immortalized cells. Interestingly, Bcl-6 is a
transcriptional repressor of both lymphocyte differentiation
and apoptosis and is the most frequently targeted proto-onco-
gene in non-Hodgkin’s lymphomas (54). LMP1 is sufficient for
this pathway, as inducible expression of LMP1 and transfection
of a plasmid encoding LMP1 were enough to repress both
FoxO1 and the target gene encoding Bcl-6. An inverse corre-
lation between LMP1 and Bcl-6 has previously been described
at the transcriptional and protein levels for the B cells of
transgenic mice expressing LMP1 or a chimeric LMP1-CD40
molecule (37). Other studies have also observed the repressive
effect of CD40 activation or EBV genome expression on Bcl-6
expression in B cells and dendritic cells (1, 10, 35). The func-
tion of Bcl-6 repression by LMP1 is believed to be germinal
center suppression, allowing exit of EBV-infected cells from
the germinal center. This study identifies FoxO1 as a molecular
intermediate by which LMP1 can regulate Bcl-6.
The role of LMP2A in the regulation of FoxO1 and Bcl-6 is
more complex. The activation of PI3K through LMP2A has
previously been shown to induce phosphorylation of FoxO1 in
epithelial cells (34), which subsequently targets FoxO1 for deg-
radation. However, the effects of LMP2A on the total protein
levels of both FoxO1 and Bcl-6 had not been defined previ-
ously. A clear downregulation of FoxO1 protein expression
was observed in this study upon LMP2A transient transfection,
but this did not translate to a corresponding dose-responsive
decrease in Bcl-6 expression. However, induction of LMP2A in
stable transfectants did result in a clear repression of Bcl-6
protein expression. This may be due to differences in the time
or level of expression. In the system with stable expression,
more LMP2A is expressed for a longer time than the 20 h
studied for the transient transfections.
In contrast to Bcl-6, an inverse correlation was observed
between cyclin D2 protein expression and that of FoxO1. We
have previously shown that PI3K regulates the cyclin D2 pro-
tein (7) and the cyclin D2 promoter (53), so this may be due, in
part, to FoxO1. However, the repressive effect of FoxO tran-
scription factors on cyclin D2 transcription may be indirect
(47), perhaps through Bcl-6, via an interaction with the STAT5
transcription factor (16). The cyclin D2 gene has a complex
promoter and is subject to regulation by a diverse range of
cellular stimuli (31, 53).
Our data have revealed a difference in the kinetics of FoxO1
regulation by the PI3K pathway between EBV-negative BL
cells and LCLs. In IARC-171 cells, 24 h of incubation with
LY294002 was required to detect an increase in nuclear
FoxO1, but 1 h was sufficient for an increase of a similar level
in the nuclei of EBV-negative BL41 cells. This suggests the
presence of extra mechanisms for the repression of FoxO1 in
EBV-immortalized cells, an observation supported by the de-
tection of lower levels of FoxO1 mRNA in these cells. A
difference in the contributions of the PI3K pathway towards
the survival of these two cell types is evident when analyzing
cell survival after treatment with the PI3K inhibitor (7). EBV-
negative BL lines rapidly undergo apoptosis; in contrast, LCL
lines do not die but are growth arrested. This difference in
sensitivity to LY294002 is also seen for other agents and may
be due, in part, to the delay in induction of FoxO1 as well as
other molecules, such as NF-B, that are increased in EBV-
immortalized cells.
Our 2D-electrophoretic analysis of DNA-bound FoxO1
showed that posttranslational modification patterns are dis-
tinct for EBV-positive B cells (BL41B95.8) compared with
those for EBV-negative B cells (BL41), suggesting a further
level of control of FoxO1. Interestingly, there was also more
than one band present in IARC-171 nuclear extracts, particu-
larly when they were treated with LY294002 (Fig. 2a). Changes
in molecular weight are often indicative of posttranslational
modification. However, the small amount of FoxO1 in these
cells precluded the analysis of FoxO1 by 2D gel electrophore-
sis. It is possible that the multiple isoforms of FoxO1 detected
bound to DNA in EBV-positive cells are differentially phos-
phorylated forms, but this is unlikely, as phosphorylation tar-
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gets FoxO1 molecules for nuclear exclusion and thus would not
be easily detected by this assay. Acetylation of nuclear FoxO
proteins has also been reported to affect the transcriptional
programs controlled by FoxO proteins due to interference with
the balance of coactivator and corepressor recruitment (19, 39,
51). Again, a role for the PI3K pathway is evident, as acetyla-
tion was reported to increase the sensitivity of FoxO1 to phos-
phorylation, contributing to degradation (32). A recent study
demonstrated the role of ubiquitinylation by the Skp2/Cul-1/
F-box-protein–ubiquitin complex in the targeting of FoxO1
molecules for degradation following PKB activation (24).
However, the pattern of spots observed did not show a signif-
icant increase in the molecular weight of the protein, which
would be suggested following ubiquitinylation. Thus, while
pathways activated by EBV lead to differential modifications of
FoxO1, as detected in BL41B95.8 cells, that may repress
transcriptional activity, their identity is unknown and currently
under investigation.
Integrating the data generated in this study provides evi-
dence that EBV regulates FoxO1 expression by three distinct
mechanisms, i.e., the prototypic repression of FoxO1 by PI3K,
alternative posttranslational modifications observed in BL41
cells infected by EBV (BL41B95.8 cells), and a repression of
FoxO1 expression at the mRNA level. These diverse mecha-
nisms ensure that FoxO1 expression and activity are inhibited.
The existence of these distinct mechanisms suggests that re-
pressing FoxO1 activity is an important part of EBV infection
of B cells.
In summary, our data identify FoxO1 as an EBV-regulated
transcription factor and, as such, add to a body of work dem-
onstrating the suppression of proapoptotic pathways by EBV.
Furthermore, we have identified FoxO1 as one of the few
proteins regulated by both LMP1 and LMP2A. Putting this in
context, LMP1 and LMP2A have been shown to activate a
diverse range of signaling pathways contributing to cell sur-
vival. These include the activation of tyrosine kinases, mitogen-
activated protein kinases, JNK, p38, the transcription factor
NF-B, and the PI3K pathway. Distinctly, this study describes
another nuclear target by which EBV latent membrane pro-
teins work to shift the balance of anti- and proapoptotic path-
ways towards survival. The interplay between EBV and FoxO1
is likely to contribute to the characteristic apoptotic resist-
ance of immortalized B cells in the context of EBV-associated
malignancies.
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